20th World Meeting on Sexual Medicine a Success!
Video Journal of Prosthetic Urology Announces New Editorial Board
The 20th World Meeting on Sexual Medicine, held September 22-25, 2016 in Beijing, China, was a great success!
We were joined by more than 800 attendees representing 58 countries. Our attendees included urologists, primary care physicians, psychologists, physician assistants, advanced practice nurses, sex counselors, OB/GYNs, and other clinicians currently treating patients with sexual health issues.
The abstracts and posters of the meeting are already available here. The presentations from the meeting will be made available on the ISSM University website soon. All ISSM members may access the ISSM University using their current ISSM website login information.
PDE5 Inhibitor Use Does Not Affect Prostate Cancer Risk
During the recent World Meeting on Sexual Medicine in China, the new Editorial Board of the Video Journal of Prosthetic Urology (VJPU) was announced by the Editor-in-Chief, Dr. Steven K. Wilson.
Since the journal's inception, Drs. Allen Morey, Lenaine Westney, and David Ralph have served on the Editorial Board of the VJPU. After three years of exemplary service, they volunteered to step down in order to give others a chance to participate.
The new Editorial Board is composed of the following doctors:
Jeff Brady, MD, FACS (USA)
Daniar Osmonov MD, PhD (Germany)
Koenraad van Renterghem, MD, PhD, FEBU (Belgium)
Ashley Tapscott, DO – (USA)
For more information about these new Board members, please visit www.vjpu-issm.info.
The ISSM would like to express its grateful appreciation for all the great work done by the previous Editorial Board members and wishes the new Board every success with the work for this important video journal.
Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, tadalafil, and vardenafil, do not reduce a man's risk for prostate cancer, according to a recent study in the Journal of Urology.
Past studies in mice found that the drugs, which are considered first-line treatment for erectile dysfunction (ED), showed a possible anticancer effect. But research on humans have had mixed results.
This study used data from the 4-year REDUCE study, which explored the relationship between dutasteride, an enlarged prostate drug, and prostate cancer risk. Men had biopsies at two- and four-year points.
For the current research, the scientists looked at data from 6,501 REDUCE participants. About 6% of the men used PDE5 inhibitors at the start. Eventually, 20% of these men were diagnosed with prostate cancer, compared to 23% of the men who did not take medication for ED.
The researchers concluded that PDE5 inhibitor use seems to have no effect on the rate or severity of prostate cancer. Please click here for more details.